ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)

SAN DIEGO, Oct. 06, 2023 -- ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions...

Related Keywords

United States ,Justin Chakma ,Richard Lowenthal ,Laura Oneill ,Allergy Drugs Advisory Committee ,Drug Administration ,Exchange Commission On ,Advisory Committee The Pulmonary ,Pharmaceuticals Inc ,Nasdaq ,Complete Response Letter ,Pulmonary Allergy Drugs Advisory Committee ,Typei Allergic Reactions ,Private Securities Litigation Reform Act ,Quarterly Report ,Exchange Commission ,Investor Contact ,Media Contact ,Markets ,